Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Remediation of IgG4 Cross-Reactivity in IgG1 and IgG2 Subclass Assays.

Parker AR, Sharp KL, Jenner EL, Coley MD, Kay AD, Harding SJ.

Clin Chem. 2018 Aug;64(8):1253-1255. doi: 10.1373/clinchem.2018.289124. Epub 2018 Jun 6. No abstract available.

PMID:
29875215
2.

Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease.

Fenton A, Jesky MD, Webster R, Stringer SJ, Yadav P, Chapple I, Dasgupta I, Harding SJ, Ferro CJ, Cockwell P.

PLoS One. 2018 May 9;13(5):e0197043. doi: 10.1371/journal.pone.0197043. eCollection 2018.

3.

Gut microbiome alterations in Alzheimer's disease.

Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE.

Sci Rep. 2017 Oct 19;7(1):13537. doi: 10.1038/s41598-017-13601-y.

4.

Serum IgG4 Concentration in IgG4-Related Disease.

Kawa S, Skold M, Ramsden DB, Parker A, Harding SJ.

Clin Lab. 2017 Sep 1;63(9):1323-1337. doi: 10.7754/Clin.Lab.2017.170403. Review.

PMID:
28879714
5.

Serum tryptase concentration and progression to end-stage renal disease.

Jesky MD, Stringer SJ, Fenton A, Ng KP, Yadav P, Ndumbo M, McCann K, Plant T, Dasgupta I, Harding SJ, Drayson MT, Redegeld F, Ferro CJ, Cockwell P.

Eur J Clin Invest. 2016 May;46(5):460-74. doi: 10.1111/eci.12622. Epub 2016 Apr 15.

PMID:
26999448
6.

Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents.

Carr-Smith HD, Jenner EL, Evans JA, Harding SJ.

Clin Chem Lab Med. 2016 Jun 1;54(6):997-1003. doi: 10.1515/cclm-2015-1068. Review.

PMID:
26943608
7.

Quantification of β-region IgA monoclonal proteins - should we include immunochemical Hevylite® measurements? Point.

Evans JA, Jenner EL, Carr Smith HD, Berlanga O, Harding SJ.

Clin Chem Lab Med. 2016 Jun 1;54(6):1053-7. doi: 10.1515/cclm-2015-0696.

PMID:
26485749
8.

Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.

Gallagher CL, Bell B, Palotti M, Oh J, Christian BT, Okonkwo O, Sojkova J, Buyan-Dent L, Nickles RJ, Harding SJ, Stone CK, Johnson SC, Holden JE.

Brain Imaging Behav. 2015 Dec;9(4):821-7. doi: 10.1007/s11682-014-9338-4.

9.

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.

Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X.

Cancer. 2014 Dec 15;120(24):3952-7. doi: 10.1002/cncr.28946. Epub 2014 Aug 12. Erratum in: Cancer. 2015 Mar 1;121(5):800.

10.

Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay.

Faint JM, Basu S, Sutton D, Showell PJ, Kalra PA, Gunson BK, Jackson CE, Mushtaq A, Assi LK, Carr-Smith HD, Cockwell P, Harding SJ.

Clin Chem Lab Med. 2014 Nov;52(11):1605-13. doi: 10.1515/cclm-2014-0279.

PMID:
24926626
11.

Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease.

Hutchison CA, Burmeister A, Harding SJ, Basnayake K, Church H, Jesky MD, White K, Green CE, Stringer SJ, Bassett P, Ferro CJ, Cockwell P.

Mayo Clin Proc. 2014 May;89(5):615-22. doi: 10.1016/j.mayocp.2014.01.028.

12.

Elevated serum free light chains predict cardiovascular events in type 2 diabetes.

Bellary S, Faint JM, Assi LK, Hutchison CA, Harding SJ, Raymond NT, Barnett AH.

Diabetes Care. 2014 Jul;37(7):2028-30. doi: 10.2337/dc13-2227. Epub 2014 Apr 17.

PMID:
24742658
13.

A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.

Li CT, Palotti M, Holden JE, Oh J, Okonkwo O, Christian BT, Bendlin BB, Buyan-Dent L, Harding SJ, Stone CK, DeJesus OT, Nickles RJ, Gallagher CL.

Synapse. 2014 Aug;68(8):325-31. doi: 10.1002/syn.21745. Epub 2014 Apr 22.

14.

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, Tzenou T, Dimou M, Georgiou G, Mirbahai L, Bradwell AR, Kyrtsonis MC.

Exp Hematol Oncol. 2012 Apr 23;1(1):9. doi: 10.1186/2162-3619-1-9.

15.

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, Harding SJ.

Leukemia. 2013 Jan;27(1):213-9. doi: 10.1038/leu.2012.197. Epub 2012 Jul 17. Erratum in: Leukemia. 2013 Apr;27(4):996.

16.

A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Gallagher CL, Christian BT, Holden JE, Dejesus OT, Nickles RJ, Buyan-Dent L, Bendlin BB, Harding SJ, Stone CK, Mueller B, Johnson SC.

Mov Disord. 2011 Sep;26(11):2032-8. doi: 10.1002/mds.23778. Epub 2011 Jun 2.

17.

Activation of ASK1, downstream MAPKK and MAPK isoforms during cardiac ischaemia.

Harding SJ, Browne GJ, Miller BW, Prigent SA, Dickens M.

Biochim Biophys Acta. 2010 Sep;1802(9):733-40. doi: 10.1016/j.bbadis.2010.06.005. Epub 2010 Jun 13.

18.
19.

Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios.

Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP.

Clin Chem. 2009 Sep;55(9):1646-55. doi: 10.1373/clinchem.2009.123828. Epub 2009 Jul 17.

20.

A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.

Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T.

Cancer Res. 2006 Jun 1;66(11):5901-9.

21.

Evaluation of heat shock protein 70 as a biomarker of environmental stress in Fucus serratus and Lemna minor.

Elyse Ireland H, Harding SJ, Bonwick GA, Jones M, Smith CJ, Williams JH.

Biomarkers. 2004 Mar-Apr;9(2):139-55.

PMID:
15370872
22.

Pi-allyloxymethyl protection of histidine.

Harding SJ, Jones JH.

J Pept Sci. 1999 Sep;5(9):399-402.

PMID:
10526882
23.

Im-trityl protection of histidine.

Harding SJ, Jones JH, Sabirov AN, Samukov VV.

J Pept Sci. 1999 Aug;5(8):368-73.

PMID:
10507686

Supplemental Content

Loading ...
Support Center